Collaborative Agreements (Tables)

9 Months Ended

Sep. 30, 2011

Summary Of Components Of Deferred Credit

	September 30, 2011						December 31, 2010
	Current		Long-term		Total		Current		Long-term		Total
Deferred credit-capitalized interest portion	$	4,762	$	44,048	$	48,810	$	—	$	44,500	$	44,500
Deferred collaborative revenue portion		7,895		65,131		73,026		—		80,500		80,500
Total	$	12,657	$	109,179	$	121,836	$	—	$	125,000	$	125,000

Lilly [Member]

Schedule Of Activity Related To Collaboration

Activity	Classification within Consolidated Statements of Operations	Three Months Ended				Nine months Ended
		September 30, 2011		September 30, 2010		September 30, 2011		September 30, 2010
Royalty revenue	Revenues under collaborative agreements	$	1,040	$	0	$	2,441	$	0
Milestone revenue and amortization of up-front payments	Revenues under collaborative agreements	$	16,974	$	0	$	16,974	$	0
Gross margin cost-sharing, net of amortization of up-front payments	Collaborative profit sharing	$	58,959	$	61,249	$	179,462	$	194,056
Development expense cost-sharing payments received from Lilly for BYETTA and BYDUREON development expense	Reduction of research and development expense	$	16,684	$	22,523	$	51,872	$	51,152
Cost-sharing payments received from Lilly for shared sales force expenses, marketing expenses and other commercial or operational support	Reduction of selling, general and administrative expense	$	3,592	$	4,061	$	9,229	$	21,873

Takeda [Member]

Schedule Of Activity Related To Collaboration

Activity	Classification  within Consolidated Statements of Operations	Three Months Ended September 30,				Nine months Ended September 30,
		2011		2010		2011		2010
Amortization of up-front payments	Revenues under collaborative agreements	$	1,875	$	1,875	$	5,625	$	5,625
Cost-sharing payments due from Takeda for shared development expenses	Reduction of research and development expense	$	10,191	$	3,992	$	17,181	$	10,175